New Obesity Pills May Change Weight Loss Game

New York, NY – Patients struggling with weight loss may soon have a more convenient treatment option as drugmakers seek FDA approval for oral obesity medications. Companies like Novo Nordisk and Eli Lilly are developing pills that could replace weekly injections.

Millions have relied on injectable treatments like Wegovy and Mounjaro, but these options are not affordable or accessible for everyone. With the rise of oral medications, patients could potentially take control of their weight loss journey.

“The patient community in the obesity space has gone without treatment for so long,” said an advocate for obesity awareness, emphasizing the need for new solutions for this chronic disease.

Two new pills are anticipated to hit the market soon. Novo Nordisk’s version contains semaglutide, the key ingredient in its existing injectables. Eli Lilly is developing its own pill, orforglipron, with a different active ingredient aimed at treating obesity.

Unlike the injectable alternatives, these pills will need to be taken daily. Novo Nordisk overcame challenges in pill formulation by incorporating sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, ensuring the medicine remains intact long enough to be absorbed in the stomach.

Eli Lilly claims its orforglipron can be taken without any food or water restrictions, making it easier for patients to incorporate into their daily routines.

Initial studies show promising results for both pills. Semaglutide led to significant weight loss over 64 weeks, while orforglipron showed slightly less efficacy.

Cost is a significant factor for potential users. Experts predict that the new pills should be less expensive than their injectable counterparts, which can cost over $1,000 per month. As a result, many are hopeful that insurance companies will provide better coverage for these pill formulations.

If approved, Novo Nordisk’s oral obesity pill may be available as soon as this year. Eli Lilly is also expected to submit its own pill for FDA approval shortly. The landscape of obesity treatment may see substantial changes in the coming months as these new options become available.